Evidence map›Paper›PMID 36173685›Full record

ArticleJCI insight2022

A heterozygous LAMA5 variant may contribute to slowly progressive, vinculin-enhanced familial FSGS and pulmonary defects.

Jun-Ya Kaimori, Yamato Kikkawa, Daisuke Motooka, Tomoko Namba-Hamano, Ayako Takuwa, Atsuko Okazaki, Kaori Kobayashi, Arisa Tanigawa, Yuko Kotani, Yoshihiro Uno and 12 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 7 institutions in 3 countries.

Jun-Ya KaimoriDepartment of Inter-Organ Communication Research in Kidney Diseases and.
Yamato KikkawaDepartment of Clinical Biochemistry, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
Daisuke MotookaGenome Information Research Center, Research Institute for Microbial Diseases, and.
Tomoko Namba-HamanoDepartment of Nephrology, Osaka University Graduate School of Medicine, Osaka, Japan.
Ayako TakuwaImmunology Frontier Research Center, Osaka University, Osaka, Japan.
Atsuko OkazakiDepartment of Genome Informatics, Osaka University Graduate School of Medicine, Osaka, Japan.
Kaori KobayashiDepartment of Genome Informatics, Osaka University Graduate School of Medicine, Osaka, Japan.
Arisa TanigawaInstitute of Experimental Animal Sciences and.
Yuko KotaniInstitute of Experimental Animal Sciences and.
Yoshihiro UnoInstitute of Experimental Animal Sciences and.
Kazuto YoshimiGenome Editing Research and Development (R&D) Center, Osaka University Graduate School of Medicine, Osaka, Japan.
Koki HattoriDepartment of Nephrology, Osaka University Graduate School of Medicine, Osaka, Japan.
Yuta AsahinaDepartment of Nephrology, Osaka University Graduate School of Medicine, Osaka, Japan.
Sachio KajimotoDepartment of Nephrology, Osaka University Graduate School of Medicine, Osaka, Japan.
Yohei DoiDepartment of Nephrology, Osaka University Graduate School of Medicine, Osaka, Japan.
Tatsufumi OkaDepartment of Nephrology, Osaka University Graduate School of Medicine, Osaka, Japan.
Yusuke SakaguchiDepartment of Inter-Organ Communication Research in Kidney Diseases and.
Tomoji MashimoInstitute of Experimental Animal Sciences and.
Kiyotoshi SekiguchiDivision of Matrixome Research and Application, Institute for Protein Research; and.
Akihiro NakayaDepartment of Genome Informatics, Osaka University Graduate School of Medicine, Osaka, Japan.
Motoyoshi NomizuDepartment of Clinical Biochemistry, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
Yoshitaka IsakaDepartment of Nephrology, Osaka University Graduate School of Medicine, Osaka, Japan.
The University of Osaka · JPInstitute of Laboratory Animal Science · CNTokyo University of Pharmacy and Life Sciences · JPJuntendo University · JPMatrix Research (United States) · USNEC (Japan) · JPThe University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The LAMA5 gene encodes laminin α5, an indispensable component of glomerular basement membrane and other types of basement membrane. A homozygous pathological variant in LAMA5 is known to cause a systemic developmental syndrome including glomerulopathy. However, the roles of heterozygous LAMA5 gene variants in human renal and systemic diseases have remained unclear. We performed whole-exome sequencing analyses of a family with slowly progressive nephropathy associated with hereditary focal segmental glomerulosclerosis, and we identified what we believe to be a novel probable pathogenic variant of LAMA5, NP_005551.3:p.Val3687Met. In vitro analyses revealed cell type-dependent changes in secretion of variant laminin α5 laminin globular 4-5 (LG4-5) domain. Heterozygous and homozygous knockin mice with a corresponding variant of human LAMA5, p.Val3687Met, developed focal segmental glomerulosclerosis-like pathology with reduced laminin α5 and increased glomerular vinculin levels, which suggested that impaired cell adhesion may underlie this glomerulopathy. We also identified pulmonary defects such as bronchial deformity and alveolar dilation. Reexaminations of the family revealed phenotypes compatible with reduced laminin α5 and increased vinculin levels in affected tissues. Thus, the heterozygous p.Val3687Met variant may cause a new syndromic nephropathy with focal segmental glomerulosclerosis through possibly defective secretion of laminin α5. Enhanced vinculin may be a useful disease marker.

Indexed as

Glomerulosclerosis, Focal SegmentalAnimalsHumansLamininMiceLamininlaminin alpha5Extracellular matrixGenetic diseasesGeneticsNephrology

Identifiers

PMID36173685
PMCPMC9746903
OpenAlexW4297965216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.